Side Effects of Opioids Are Ameliorated by Regulating TRPV1 Receptors

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Feb 25

PMID 35206575

Authors

Xiaqing Wang

Chongyu Bao

Zhenjiang Li

Lupeng Yue

Li Hu

Affiliations

Soon will be listed here.

Abstract

Humans have used opioids to suppress moderate to severe pain for thousands of years. However, the long-term use of opioids has several adverse effects, such as opioid tolerance, opioid-induced hyperalgesia, and addiction. In addition, the low efficiency of opioids in controlling neuropathic pain limits their clinical applications. Combining nonopioid analgesics with opioids to target multiple sites along the nociceptive pathway may alleviate the side effects of opioids. This study reviews the feasibility of reducing opioid side effects by regulating the transient receptor potential vanilloid 1 (TRPV1) receptors and summarizes the possible underlying mechanisms. Blocking and activating TRPV1 receptors can improve the therapeutic profile of opioids in different manners. TRPV1 and μ-opioid receptors are bidirectionally regulated by β-arrestin2. Thus, drug combinations or developing dual-acting drugs simultaneously targeting μ-opioid and TRPV1 receptors may mitigate opioid tolerance and opioid-induced hyperalgesia. In addition, TRPV1 receptors, especially expressed in the dorsal striatum and nucleus accumbens, participate in mediating opioid reward, and its regulation can reduce the risk of opioid-induced addiction. Finally, co-administration of TRPV1 antagonists and opioids in the primary action sites of the periphery can significantly relieve neuropathic pain. In general, the regulation of TRPV1 may potentially ameliorate the side effects of opioids and enhance their analgesic efficacy in neuropathic pain.

Citing Articles

Effect of electroacupuncture on pain after periodontal flap surgery: a randomized controlled trial.

Bulut E, Zkal Emino Lu D, Ay R Y J Tradit Chin Med. 2025; 45(1):184-191.

PMID: 39957173 PMC: 11764923. DOI: 10.19852/j.cnki.jtcm.2025.01.018.

Electroacupuncture Mitigates TRPV1 Overexpression in the Central Nervous System Associated with Fibromyalgia in Mice.

Anh D, Lin Y Life (Basel). 2025; 14(12.

PMID: 39768313 PMC: 11678918. DOI: 10.3390/life14121605.

TET1-Lipid Nanoparticle Encapsulating Morphine for Specific Targeting of Peripheral Nerve for Pain Alleviation.

Yang H, Liu Z, Liu F, Wu H, Huang X, Huang R Int J Nanomedicine. 2024; 19:4759-4777.

PMID: 38828199 PMC: 11141738. DOI: 10.2147/IJN.S453608.

Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels.

Bernal-Cepeda L, Jimenez R, Velandia-Romero M, Acosta-Guzman P, Castellanos J Pharmaceutics. 2024; 16(3).

PMID: 38543249 PMC: 10975074. DOI: 10.3390/pharmaceutics16030355.

LINC00960 affects osteosarcoma treatment and prognosis by regulating the tumor immune microenvironment.

Zhang Y, Lu G, Guan Y, Xu T, Duan Z, Li G Heliyon. 2024; 10(3):e24990.

PMID: 38352756 PMC: 10862516. DOI: 10.1016/j.heliyon.2024.e24990.

References

Waldhoer M, Bartlett S, Whistler J . Opioid receptors. Annu Rev Biochem. 2004; 73:953-90. DOI: 10.1146/annurev.biochem.73.011303.073940. View

Laing R, Dhaka A . ThermoTRPs and Pain. Neuroscientist. 2015; 22(2):171-87. PMC: 4510032. DOI: 10.1177/1073858414567884. View

Marinelli S, Pascucci T, Bernardi G, Puglisi-Allegra S, Mercuri N . Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology. 2004; 30(5):864-70. DOI: 10.1038/sj.npp.1300615. View

Iftinca M, Defaye M, Altier C . TRPV1-Targeted Drugs in Development for Human Pain Conditions. Drugs. 2020; 81(1):7-27. DOI: 10.1007/s40265-020-01429-2. View

Roeckel L, Utard V, Reiss D, Mouheiche J, Maurin H, Robe A . Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide. Sci Rep. 2017; 7(1):10406. PMC: 5583172. DOI: 10.1038/s41598-017-11120-4. View

Rowan M, Szteyn K, Doyle A, Gomez R, Henry M, Jeske N . β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons. Mol Pain. 2014; 10:50. PMC: 4131480. DOI: 10.1186/1744-8069-10-50. View

Abdullah N, Altier C . TRPV1 and MOR working in tandem: implications for pain and opioids use. Neuropsychopharmacology. 2019; 45(1):225-226. PMC: 6879763. DOI: 10.1038/s41386-019-0516-3. View

Gerdjikov T, Ross G, Beninger R . Place preference induced by nucleus accumbens amphetamine is impaired by antagonists of ERK or p38 MAP kinases in rats. Behav Neurosci. 2004; 118(4):740-50. DOI: 10.1037/0735-7044.118.4.740. View

Nguyen T, Nam Y, Lee S, Kim H, Jang C . Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice. Br J Anaesth. 2010; 105(5):668-74. DOI: 10.1093/bja/aeq212. View

10.

Ma S, Kim H, Lee S, Jang C . TRPV1 modulates morphine self-administration via activation of the CaMKII-CREB pathway in the nucleus accumbens. Neurochem Int. 2018; 121:1-7. DOI: 10.1016/j.neuint.2018.10.009. View

11.

Yao Z, Kamau P, Han Y, Hu J, Luo A, Luo L . The Caterpillar Induces Pain by Targeting Nociceptive Ion Channel TRPV1. Toxins (Basel). 2019; 11(12). PMC: 6950366. DOI: 10.3390/toxins11120695. View

12.

Garami A, Shimansky Y, Rumbus Z, Vizin R, Farkas N, Hegyi J . Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. Pharmacol Ther. 2020; 208:107474. DOI: 10.1016/j.pharmthera.2020.107474. View

13.

Basso L, Aboushousha R, Fan C, Iftinca M, Melo H, Flynn R . TRPV1 promotes opioid analgesia during inflammation. Sci Signal. 2019; 12(575). DOI: 10.1126/scisignal.aav0711. View

14.

Luo J, Bavencoffe A, Yang P, Feng J, Yin S, Qian A . Zinc Inhibits TRPV1 to Alleviate Chemotherapy-Induced Neuropathic Pain. J Neurosci. 2017; 38(2):474-483. PMC: 5761620. DOI: 10.1523/JNEUROSCI.1816-17.2017. View

15.

Ma S, Kwon S, Seo J, Hwang J, Hong S, Kim H . Impairment of opiate-mediated behaviors by the selective TRPV1 antagonist SB366791. Addict Biol. 2016; 22(6):1817-1828. DOI: 10.1111/adb.12460. View

16.

Pelloux Y, Giorla E, Montanari C, Baunez C . Social modulation of drug use and drug addiction. Neuropharmacology. 2019; 159:107545. DOI: 10.1016/j.neuropharm.2019.02.027. View

17.

Bohn L, Lefkowitz R, Gainetdinov R, Peppel K, Caron M, Lin F . Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 2000; 286(5449):2495-8. DOI: 10.1126/science.286.5449.2495. View

18.

Fields H, Emson P, Leigh B, Gilbert R, Iversen L . Multiple opiate receptor sites on primary afferent fibres. Nature. 1980; 284(5754):351-3. DOI: 10.1038/284351a0. View

19.

Chen Y, Geis C, Sommer C . Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci. 2008; 28(22):5836-45. PMC: 6670790. DOI: 10.1523/JNEUROSCI.4170-07.2008. View

20.

Costigan M, Scholz J, Woolf C . Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009; 32:1-32. PMC: 2768555. DOI: 10.1146/annurev.neuro.051508.135531. View